T. Baker

CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer

M. Wicha, S. Eliasof, S. Clouthier, 2015, Breast Cancer Research and Treatment.

RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Michael D. Brooks, M. Wicha, J. Colacino, 2016, Clinical Cancer Research.

Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer

H. Kluger, W. Zheng, S. Chambers, 2009, Oncogene.

SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model

Dafydd G. Thomas, M. Wicha, A. Prat, 2014, Oncogene.